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A B S T R A C T   
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to focus on 
global peace engineering and innovation. Where, any single orphan disease is rare, when taken as a whole they 
affect more than 250 million people throughout the world. This number by comparison is larger than the global 
number of cancer and AIDS patients. We add to the literature by mapping the available knowledge in the orphan 
drug development field and exploring the tensions at play for innovation and entrepreneurship in this field. We 
further add to the literature by providing a framework to review this field based on social systems theory. Our 
review highlights the gaps in research and proposes a path forward in understanding of and learning from the 
orphan drug development field.   
INTRODUCTION 
Rare diseases pose a challenge to society on a global scale. Although 
most of these diseases have a prevalence of less than 10 patients per 1 
million inhabitants (Aymé and Hivert, 2011), together they affect at 
least 250 million people around the world (Grossman et al., 2014). 
However, for nearly 7000 rare diseases, fewer than 5% have at least one 
approved pharmacotherapy (Hechtelt Jonker et al., 2020; Wood et al., 
2013). This means that most of the individuals affected by these dis-
eases are being deprived of basic needs, such as proper diagnosis, 
treatment, and a cure (Certo and Miller, 2008), thus offering opportu-
nities for global peace engineering and innovation. 
For those of the rare diseases, where medical treatment or cure are 
possible, challenges for developing them include the limited knowledge 
available for most diseases, the difficulties of generating adequate ef-
ficacy and safety data in small populations and the risk of financial 
unsustainability for both developers and health-care systems 
(Hechtelt Jonker et al., 2020). Although governments intervene, their 
efforts alone are not sufficient to close the market gap that results from 
the on average small market potential of each rare disease. Orphan drug 
(OD) development is an area where governments, patient communities, 
knowledge institutes, and private actors such as foundations and social 
impact‒oriented enterprises actively work together on socially accep-
table, sustainable, and desirable innovation to overcome this global 
challenge. 
With this paper we offer a critical review of the current academic 
literature about OD development. Drawing on social systems theory 
(Groen, 2005; Parsons, 1964;1977), we develop an analytical frame-
work to identify main themes and contributions in the goal setting, 
adaptation, integration, and pattern maintenance mechanisms of the 
OD field. We then discuss the extent to which this literature reflects the 
recent changes in the field and propose a path forward for future re-
search. 
Our results show that the current debate in the literature relies 
heavily on an economic logic of analysis, which would benefit from 
reframing into more systemic thinking in order to include the needs and 
voices of a broader range of stakeholders. We further note that existing 
narratives in scientific, regulatory, and public discussions “established a 
locus of responsibility for orphan drugs in the … government” 
(Grossman, 1984, p.151) while overlooking alternative solutions cur-
rently being implemented by the stakeholders of the rare disease 
community. Applying a multi-level deconstruction to the publications 
in the OD field, we note important gaps in the research. Among others, 
future research could explore the roles and boundaries of the stronger 
and more visible participation from the patients and patient commu-
nities, acknowledge the antecedents and impact of technological ad-
vances for novel business models, and study the mechanisms of gov-
ernance of multilateral stakeholder collaboration networks. These 
trends may augment the measures already offered by governments and 
stimulate new opportunities for peace engineering and innovation thus 
contributing to solving this global challenge and furthering the goals of 
a sustainable and peaceful society. 
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We followed the planning, execution, and reporting procedure for 
systematic literature review of Tranfield et al., (2003). During the 
planning stage, we defined the objectives of the research and identified 
the key data source. Our objective was to describe and systematize the 
academic publications and discussions on OD development. For this 
purpose, we searched the ISI Web of Knowledge Social Sciences Citation 
Index (SSCI) database for relevant studies in journals published in 
English. This database was selected because it is one of the most 
comprehensive databases of peer-reviewed journals in the social sci-
ences. As we are interested in innovation and entrepreneurship in the 
drug development process for rare diseases, the search items were: 
“orphan drug” and “rare disease drug.” We did not conduct searches for 
individual technologies, components, or any of the 7000 specific dis-
eases. 
The search was conducted in November 2017 and resulted in 477 
records from all years and journals registered in the database. We fur-
ther focused on double-blind review papers and excluded open-access 
articles and conference abstracts, assuming they represent the dominant 
discussions within the field. The refined sample contained 179 records. 
Next, as the search triggered results on drug use among orphans, we 
excluded categories such as “rehabilitation,” “substance abuse,” “tox-
icology,” and “immunology” reducing number of records by 23. After 
screening the abstracts and full texts, we manually removed further 26 
articles that did not deal directly with rare diseases, which left us with a 
sample of 130 articles. 
The selected articles had appeared in 70 outlets ranging from 
medical to law and economics journals, with a majority of the outlets 
having only one or two articles. Nine articles appeared between 1984 
and 1995, 18 articles between 1996 and 2006, 43 articles between 2007 
and 2012, and 60 between 2013 and 2017. 
Analytical framework 
To structure our analysis of innovation and entrepreneurship in the 
development of ODs, we drew on the structural-functional sociological 
theory of Talcott Parsons (Parsons, 1964,1977) and its adaptation to 
entrepreneurship by Groen (2005). Social systems theory allows an 
understanding of developments in society (Parsons, 1977), and the 
adaptation to entrepreneurship can shed new light on the growth of 
entrepreneurial developments and the adoption of new technology 
(Groen et al., 2008; Heuven and Groen, 2012; Leloux and Groen, 2007;  
Middel et al., 2007; Pullen et al., 2012). 
A social system was originally defined as “a plurality of individual 
actors interacting with each other in a situation, which has at least a physical 
or environmental aspect, actors who are motivated in terms of a tendency to 
the ‘optimization of gratification’ and whose relation to their situations, 
including each other, is defined and mediated in terms of culturally struc-
tured and shared symbols” (Parsons 1964, pp. 5‒6). Following this de-
finition, the four functional requisites of any system of action include: 
(A) adaptation or optimization of processes, (G) striving for goal at-
tainment, (I) integration through interaction between actors, and (L) 
latent pattern maintenance of culturally structured and shared symbols 
(Groen, 2005; Murphy, 2005). This framework is traditionally thought 
to be pretty intuitive: A viable system needs to adapt to the changes in 
the external world, while defining, achieving, and defending its goals 
regarding which the members of the system interact and communicate 
to come to a sustainable level of integration and build order and main-
tain this in a latent pattern maintenance dimension of the social system. 
These mechanisms known as AGIL lay the basis of our multi-dimen-
sional framework to analyze the viability of the OD development space. 
Furthermore, to introduce a multi-level perspective we grouped the 
contributions into three levels – macro (global, national, and 
international issues), meso (industry, market, technology), and micro 
(individual actors). The definitions adopted here thus differ from the 
more traditional socio-institutional understanding of micro-, meso‑, and 
macro- within healthcare field (Smith et al., 2019). Our approach builds 
instead on the ideas of the socio-technical dynamics models 
(Clark, 1985; Rip and Groen, 2001) and specifically, the perspective of 
“many visible hands,” (Rip and Groen, 2001) where, instead of having 
market or government dominance in the development process, a mul-
titude of actors is assumed to develop the innovation and its applica-
tion, leading to an embeddedness approach (Granovetter, 1985;  
Laumann and Pappi, 1976). This approach offers a higher promise for 
the purpose of understating of the mechanisms for innovation and en-
gineering of a peaceful, sustainable society. 
Analysis of the contributions 
Combining these two approaches, we read the full texts of the ar-
ticles in the review and coded them according to the unit of analysis, 
and the main mechanism of interaction, following the AGIL model. 
Adaptation. Here we grouped articles that describe how social sys-
tems cope with their external boundary conditions, such as their re-
source base, physical environment, and territory (Groen, 2005). As 
economic activity often serves to solve problems of adaptation, at a 
macro we looked for articles covering national budget instruments and 
concerns about national and societal budget impact of rare diseases. 
Articles covering the economic activity of markets, common business 
(revenue) models and pricing strategies were coded as adaptation on 
meso level. At a firm (micro) level, we coded articles reporting in-
dividual cases of drugs or firms. 
Goal attainment. The goals of any social system have to be defined, 
prioritizing some over others, determining resource allocations, and 
directing social energies. Political activity organizes and directs the 
goal attainment on a macro level. Hence, issues of legislation, prior-
itization, and ethical implications of rare diseases were coded into this 
category. At the same time, a plurality of actors, including institutional 
systems, define the order, power, and hierarchy at the market and in-
dustry (meso) levels. At the micro level of an individual firm, goal at-
tainment is reflected in the power of an organization “to decide on goals 
and to control resources and other actors to attain them” (Groen, 2005). 
Integration. All of the adaptive efforts of social institutions within a 
society need to be integrated into a cohesive and harmonious system. 
Individual actor networks form the micro level, while stakeholder re-
lationships and interactions reside at the meso (industry or regional) 
level, and international relations and collaborations determine in-
tegration on the macro level. 
Latency. The pattern maintenance function creates a state of (tem-
porary) order in a symbolic system of values, norms, beliefs, assump-
tions, symbols, rule sets, and artifacts and it must be maintained and 
renewed (Groen, 2005). It allows for learning and change and, at the 
same time, makes up the identity and culture of a system (Groen, 2005). 
Fiduciary systems such as families, schools, and churches solve these 
problems of pattern/tension management at a societal level. Industry 
level standards and regulations set up the norms and rules on the meso 
level, and reflect the technological trends by embracing (or not) novel 
technologies and changes they bring. Knowledge accumulation, pro-
ducts, and the norms of an individual actor reside at the micro level. 
Table 1. presents the overview of the results of the analysis. 
RESULTS 
We present the main findings along the AGIL model dimensions. 
Adaptation 
Out of 130 contributions, only 22 discuss the adaptation (economic) 
mechanism of ODs. We could identify the following main lines of 
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discussion: (a) the macro issues of ODs’ impact on public budgets, re-
imbursement, and expenditures; (b) the meso issues of profitability and 
of companies entering the OD field; and (c) micro-level analysis of the 
costs of specific drugs. 
First and foremost, in the discussion of the impact that ODs have on 
public budgets, there seems to be implicit consensus that, with the 
stimulation of OD development and the value-based (often, very high) 
pricing used, ODs can become an unbearable burden on society 
(Benjamin et al., 2017; Michel and Toumi, 2012). Some technological 
trends further reinforce this concern: With the adoption of pharmaco-
genomics, precision medicine will allow many more medications to 
qualify under OD regulations, which could further increase this impact 
on the budget (Danzon and Towse, 2002; Loughnot, 2005) and have 
even larger societal consequences. 
However, other contributions in the review show that only a few 
ODs enjoy very high sales and around 90% of this sales volume comes 
from “common disease” patients and not patients with a rare disease 
which is possible for ODs with non-orphan indications (Divino et al., 
2016). Furthermore, Maresova et al., (2016) show that ODs influence 
between 2 and 11% of the budget impact and do not represent an im-
mediate threat to the system of public health insurance. Similarly,  
Schlander et al., (2015) assessed both existing and still in the pipeline 
drugs for ultra-rare diseases and concluded there will be no threat for 
the next 10 years. Hence, there are two distinct lines of discussion in the 
literature. While some authors alert for the possible threat of OD for the 
public budgets, others seem to argue that facts do not support these 
fears. 
The second major discussion within the macro economics of the ODs 
focused on the effectiveness, profitability, and methods used to assess 
the value of ODs. Bruyaka et al., (2013) found that the rare disease 
market is capable to generate two-digit growth and allows for innova-
tions in the treatment of more common and widespread diseases to be 
reused, thereby increasing the return on investment. Grabowski and 
Vernon (2000) observed that drugs from the late 1990s included more 
blockbusters with higher reimbursement rates per treatment, or com-
bining OD status for some indications with approval for other non-or-
phan indications. Approximately one-fifth of the FDA approved drugs in 
the past 20 years have designations in orphan and non-orphan indica-
tions, among them Avastin, Opdivo, Enbrel, Herceptin, Humira and 
Remicade. Lazonick and Tulum (2011) further explore the fact that 
given the 10–20 year time-frame for developing biotech products and 
the lack of profitability of the industry as a whole, the US biotech boom 
should not have happened. They report that thanks to the existence of 
the speculative stock market venture capitalists in US biopharma are 
able to generate returns on their investment in ODs through IPO before 
the product was marketed, even if it was not brought to the market at 
all. This discussion stands in surprisingly stark contrast with the idea 
that ODs are unprofitable and unattractive for business. Are there cir-
cumstances under which ODs can be a basis for sustainable business 
model? 
The insights from the market (meso) level analysis and show there 
may also be a dark side to the OD business practices. Here, many re-
searchers signal the unfair play that allows niche-buster profits to be 
reaped, such as relabeling to expand patient categories (Berlin, 2009), 
stratification (“salami slicing”) (Abramowicz, 2011; Boon et al., 2008;  
Goldman, 2000; Loughnot, 2005), or the manipulation of reimburse-
ment negotiations (Coyle et al., 2014; Hemphill, 2010; Rachul et al., 
2016). Thus, there is an important ongoing discussion about unethical 
behavior within the OD field. Which prompt questions for further re-
search on the dark side (and how to eliminate it) of OD business: Has 
the phase where governments needed to stimulate the involvement of 
business into OD development passed, and is there now a need to 
control it instead? This brings us to the discussion of the goal attain-
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Goal attainment 
We identified 49 articles describing and discussing the goal attain-
ment function in the OD field and analyzing whether ODs is a strate-
gically interesting opportunity for business. The split across levels 
shows that the researchers’ primary concern is the macro level: In total, 
29 articles focus on the national level and discuss the role of govern-
ment and legislation pertaining to ODs, along with ethical questions of 
societal welfare distribution between rare and common disease treat-
ment development. At the meso level, we identified 16 articles dis-
cussing the issues of the motivations and roles of alternative actors in 
the field. Just two articles discuss the micro level. Only one article 
addressed multilevel issues. 
At the macro level, in contrast with the economic discussion, reg-
ulatory literature focuses on stimulating drug development in the OD 
field. The OD market has very high entry barriers. Small patient pools 
mean limited and weak clinical data at the time of the product launch, 
and that R&D costs need to be recouped from smaller sales which re-
sults in relatively high prices (Boon et al., 2015). This situation led to 
the enactment of the Orphan Drug Act (ODA) in 1983 in the US and 
similar subsequent statutes in other countries [Japan in 1993, Australia 
in 1997, and the European Union (EU) in 1999] (Bruyaka et al., 2013). 
These regulations provide incentives that include financial support, tax 
credits, and extended market exclusivity (Murphy et al., 2012) for OD 
sponsors, where “there is no reasonable expectation that the costs of de-
veloping and making available a drug … will be recovered from sales” 
(Arno et al., 1995, p. 234). While OD regulations have proved to be an 
effective tool in stimulating the development of rare disease therapies 
(de Vrueh, 2014), they remain under constant scrutiny. 
Already early reflections on the ODA have highlighted that, under 
pressure from the pharmaceutical companies, the “reasonable profit” 
criteria have been approximated by the size of the affected population, 
which, in return, has allowed some companies to create blockbuster 
profit models (Arno et al., 1995). Numerous alternative approaches to 
market regulation in order to allow compensation for a fair effort while 
preventing a strain on regulations have been suggested. They include 
defining what profitability means, as well as the period of time over 
which profitability is assessed (Denis et al., 2010), introducing a profit 
cap (Godman et al., 2015), considering differential pricing 
(Murphy et al., 2012), allowing competitive bids instead of market 
exclusivity (Abramowicz, 2011), or experimenting with alternative tax 
credits and price tiers (Kanavos and Mossialos, 1999; Valverde et al., 
2012; Villa et al., 2009; Yin, 2008). However, adoption of these mea-
sures has been scarce. 
Following the discussion about effectiveness of the incentives for 
entering the OD market, the ethical issues of distributive justice is an-
other dominant theme: Is it justified to sponsor ODs using limited public 
funds? The combination of substantial prices and high degrees of un-
certainty in OD development leads to complex decision making about 
the approval and reimbursement of ODs (Boon et al., 2015). Indeed, 
many ODs are so expensive that they fail to meet the standards of HTA 
cost-effectiveness criteria for reimbursement from public funds. This 
raises concerns that patients with rare diseases are disadvantaged by 
the system and questions the use of standard cost-effectiveness criteria 
for ODs. Many contributions in the review discuss the effectiveness of 
HTA-based decision-making frameworks (Salas-Vega et al., 2016;  
Wagner et al., 2016) and solicit societal responses regarding preference 
for the treatment of rare vs. non-rare diseases (Desser, 2013;  
Desser et al., 2010; Mentzakis et al., 2011; Wiss et al., 2017). These 
studies, however, highlight issues of relying on public polls, such as 
potential biases of societal preference for prioritizing rarity 
(Desser, 2013), choice under conflict (Tversky and Shafir, 1992), zero- 
sum framing (Dragojlovic et al., 2015), and the unacceptability of dis-
crimination based on social and biological attributes (Boy et al., 2011), 
suggesting that this approach is far from ideal to solve the problem. 
Furthermore, there seems to be a discrepancy between the macro 
and micro levels of demands and expectations. While legal and eco-
nomic incentives established by the regulations improve the economic 
attractiveness of OD development, “none of them taken separately is ty-
pically sufficient alone to motivate orphan drug development” 
(Bruyaka et al., 2013, p.56). Bruyaka et al., (2013) identified that 
“Exclusivity is an incentive but it is not what makes firms go into the orphan 
drug space; rather it is the good match for the technology that company 
holds” (p.57). Beyond the economic, legal and technological reasons, 
the literature also reports the upcoming engagement of families and 
philanthropies in developing new OD ventures (Davies et al., 2017;  
Wood et al., 2013). 
Latent pattern maintenance 
The latency or pattern maintenance function creates a state of 
(temporary) order in a symbolic system of values, norms, beliefs, as-
sumptions, symbols, rule sets, and artifacts (Groen, 2005). We identi-
fied 55 articles distributed over four core themes: (a) content and ap-
plication of norms and regulations within and across countries (macro); 
(b) knowledge systems and technology dynamics (meso); (c) micro/ 
meso/macro level discussion of the regulation's implementation guide-
lines and cross-level collaboration; and (d) patient experiences (micro). 
The regulatory statutes are a central theme for most (34) of the 
articles, comparing the content, process, and effects of the legislation 
within (Moors and Faber, 2007; Pauwels et al., 2015; Wonder and 
Chin, 2015) or across countries (Blankart et al., 2011; Denis et al., 
2010). What becomes apparent is that implementation differs sig-
nificantly from one country to the next. Even though some authors 
argue for significant differences between the US and Canada 
(Herder, 2013), the EU is probably affected the most because of its 
linguistic, economic, and legislative diversity (Denis et al., 2010;  
Nicod and Kanavos, 2016; Picavet et al., 2012; Richter et al., 2015). The 
discussion here often concludes with calls for greater harmonization 
and integration across regulations in order to create larger markets for 
firms, facilitate transparent decision making, and ensure better acces-
sibility of drugs for different categories of patients, including low-in-
come, ethnic, high-risk, or late-stage patients (Alqahtani et al., 2015;  
Iskrov et al., 2012; Rai, 2002; Rosselli et al., 2012). 
On the meso level, we can observe a separate discussion focused on 
technological advancement and knowledge accumulation. A large 
proportion of rare diseases have a genetic origin. Therefore, novel 
therapies mostly come from technology fields related to genetics, such 
as biotechnology, gene therapy, and pharmacogenomics (Boon et al., 
2008). However, a significant amount of time is still needed for these 
emerging technologies to reach maturity (Avery, 2010; Boon and 
Moors, 2008) as their advancement depends on the availability of ge-
netic information (Ferlini et al., 2013). Owing to the huge geographical 
dispersion of patients and experts, advocacy groups often lack the funds 
to support individual biorepositories or to locate and participate in 
existing ones. Hence, most of repositories suffer from duplications, in-
correct terminology, platform incompatibility, or are proprietary and 
not available to all investigators (Benjamin et al., 2017). Nevertheless, 
this effort is crucial to sharing and exchanging data and to developing 
studies in a meaningful way (Rubinstein, 2013). 
Novel funding schemes are also important when it comes to steering 
the application of the new technologies to areas of market failure, 
where multinational companies’ market strategies drive the innovation 
trajectories of life sciences into more profitable streams (Milne and 
Tait, 2009). Olivier and Williams-Jones (2014) have suggested that 
research based on pharmacogenomics knowledge and technologies re-
plicates the 90/10 health gap ratio in mainstream drug development 
and falls short of the promise to help increase justice in global health. 
Several initiatives are being developed to solve this challenge 
(Groft and Rubinstein, 2013), and experts suggest that European re-
positories available to researchers, foundations, and small startups 
could play a pivotal role (Denis et al., 2010). 
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Furthermore, the literature at the meso level describes the diverse 
pathways of developing an OD, including drug discovery, rediscovery, 
and redirection and identifying potential new uses for compounds that 
have undergone significant R&D by the industry. By using compounds 
that have already cleared key regulatory steps, repurposed drugs make 
it possible to accelerate the pace of therapeutic development. An op-
posing yet similar discussion is focused on groundbreaking, transfor-
mative drugs that, while designed to treat rare diseases, become 
transformative by opening up new therapeutic pathways or establishing 
a new understanding of pathology, thereby producing a much greater 
societal impact than initially expected. Kesselheim et al., (2015) and  
Groft and Rubinstein (2013) found that public–private partnerships 
combining publicly funded basic research with further development 
through collaboration between public and private entities have played a 
key role in discovering such drugs. 
A handful of contributions at the micro level of cultural patterns 
discussion explore the meaning of “being rare.” Huyard (2009) and  
Kesselheim et al., (2015) found that the biggest discomfort of rare 
disease patients relates to the process of diagnosis and that the search 
for a cure is not deemed the absolute goal one might have expected it to 
be. Both research teams acknowledged that their respondents would be 
satisfied with honest and reasonable efforts to gradually improve their 
situation. Research of Huyard (2009) highlighted the importance of 
providing patients and parents with action‐oriented and ability‐related 
information, while Kesselheim et al., (2015) reports the readiness of 
patients to be involved “beyond the normal understanding of risk”. Similar 
thinking underlies the works on patient-centered drug approval 
(Mattingly and Simoni-Wastila, 2017) and evaluation (Kimman et al., 
2017; Menon et al., 2015), which explore opportunities for patient in-
volvement to reduce uncertainty in decision making. Some even suggest 
the leading role of parents and patients in accelerating research and 
developing treatment for their diseases (Wood et al., 2013). 
Integration 
Our review noted multiple mentions of the importance of networks, 
networking, and ecosystems as they allow learning across patient 
groups, regulatory bodies, and industry (Boon and Broekgaarden, 2013;  
Boon et al., 2008,2011). For example, realizing the importance of joint 
effort in developing therapies for rare diseases has resulted in the 
formation of a cooperative initiative within a national and suprana-
tional context among the EU, Canada and the USA, and the Interna-
tional Rare Diseases Research Consortium (IRDiRC) (Ferlini et al., 
2013). The many patient-led and governmental networks, such as 
NORD in the USA, CORD in Canada, EURORDIS in Europe, pan-Eur-
opean networks (ERN), IRDiRC are doing tremendous jobs in educating 
patient and patient advocacy groups, connecting medical professionals 
and industry representatives, collecting insights from all of these sta-
keholders and helping with developing guidelines and roadmaps for 
future development (Benjamin et al., 2017). Collaborative initiatives 
further influence decision making through broader stakeholder in-
volvement by seeking comments for refining the scope and nature of 
HTA projects, considering suggestions of health technology topics, or 
even deeper involvement such as committee participation in the de-
velopment of HTA protocols (Douglas et al., 2015). They further 
highlight the need and importance of doing so at every stage of the OD 
development (Godman et al., 2015). These activities and networks 
further make possible novel ways of financing, for example, through 
venture philanthropy (Davies et al., 2017; Feldman and Graddy- 
Reed, 2014). 
Despite the prominence of the discussion on the need for colla-
boration and integration, surprisingly few contributions focused on 
studying the mechanisms underlying and enabling this function in OD 
development. 
DISCUSSION 
The multilevel, multidimensional framework 
The previous sections have identified the main themes of the re-
view, the main discussions and stumbling points. Fig. 1 combines the 
four dimensions AGIL framework and the three core levels of analysis 
(micro, meso, and macro) to highlight the expected dynamics of pattern 
renewal and change in the OD field. 
This review allowed us to observe some recent trends. These are: (a) 
even stronger and more visible participation from the patients and 
patient communities, leading to more intense interactions across the 
micro and meso levels; (b) technological advances making novel pro-
cesses and business models possible, shifting the relationships at the 
meso level, and requiring broader stakeholder involvement; and (c) the 
Fig. 1. Areas of development and future research in OD field for responsible innovation and entrepreneurship.  
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increasing role of multilateral organizations at the interface of meso and 
macro levels that collaborate across different types of stakeholders 
(governments, industry, science, patients) and steer the future agendas. 
The following sections discuss these trends and their implications in 
the context of broader literature on innovation and entrepreneurship, as 
well as in the context of the recent trends identified by the Rare2030 
project. This project led a series of interviews and focus groups with 
hundreds of the stakeholders in the field regarding the important trends 
that were going to affect the rare disease field overall. The working 
group came up with a set of 12 important trends in political, economic, 
socio-cultural and technological areas, highlighting their primary dri-
vers and indicators, and outlining the opportunities and threats they 
present. Although this report is but one of the excellent working 
documents prepared by the national and international organizations of 
the rare disease field, its specific foresight orientation provides a great 
opportunity to formulate future research avenues. 
The Rare2030 trends 
Among the trends identified by the Rare2030 project, the first one 
(T1) suggests the rise of the multi-stakeholder networks increasingly 
collaborating with actors from complimentary fields to advance diag-
nostics, treatment and care for rare diseases. Two further trends reflect 
on the economic tendencies of budget strains (T2) and inequality of 
access due to OD pricing (T3). These trends suggest that as healthcare 
budgets continue to strain, rare diseases “compete” with more in-
creasingly prevalent diseases. Meanwhile high market prices of orphan 
medicinal products result in their heterogeneous availability and ac-
cessibility. 
Trends 4,5,6 and 7 reflect the changes in the socio-cultural dimen-
sion, highlighting the longer life span of rare disease patients (T4), push 
for a more inclusive and solidary society (T5), increasingly empowered 
rare disease patient and the patient advocacy evolution (T6), and fi-
nally, rise in innovation-oriented, multi-stakeholder, needs-led (patient- 
led) research (T7). As more people with rare diseases are living longer, 
this creates new challenges such as reproductive choices, transition into 
adolescent/adult care, comorbidities of aging and age related diseases. 
This also provides a better understanding of the natural history of many 
rare diseases. The increased efforts for solidarity and equity on the 
global scale may lead to the efforts for integration of people living with 
rare diseases and related disabilities in society, and have thus the po-
tential to counterbalance the inequality of access to ODs. At the same 
time the lack of disease-modifying treatments and devices for the vast 
majority of rare diseases suggests continued gaps in design, execution, 
delivery, and ultimately the outputs of rare disease research. This re-
quires and leads to a globalization of efforts. A rise in needs-led ob-
jectives and co-creation are a few of the trends filling these gaps. 
Together with the increasingly empowered patient and patient ad-
vocacy community, the report predicts a new era in patient partnership. 
Finally, technological changes reflect on the increasing role of di-
gital health (T8), large data sets (T9), use of AI (T10), advanced tech-
nologies and therapeutics (T11), and finally genome sequencing (T12). 
The potential of large sets of standardized and interoperable data that 
can help advance understanding of RD and accelerate research is in-
creasingly recognized. Therefore, the ability to share, pool, or at least 
query data from disparate resources, ideally across borders, is essential. 
Yet, the rise in the use of AI for diagnostics, treatment and care, 
opening-up the potential of big data for diagnostics, treatment and care 
remains limited in the field of rare diseases and still requires significant 
regulatory attention. New technologies such as gene editing and ad-
vanced therapeutics including precision medicine introduce break-
through opportunities to improve the lives of people living with rare 
diseases (but also potential undesirable consequences). Finally, with a 
great majority of rare diseases being genetic, advances in the tech-
nology around Next Generation Sequencing (NGS) offer significant 
promise for unraveling the epidemiology of rare disease, accelerating 
accurate diagnosis and better targeting treatments. The potential of the 
novel technologies may be enhanced by the entry of less-traditional, 
‘disruptive’ traditional technology companies to the orphan medicinal 
product development space, which may see new approaches to bringing 
drugs to market. 
From a wicked problem towards a shared definition 
Global challenges are “wicked problems” (Buchanan, 1992;  
Reinecke and Ansari, 2016). The concerted actions of multiple stake-
holders – producers, users, and especially regulators – are necessary to 
overcome them, but a shared problem definition is a prerequisite for 
constructive dialog (Moors and Faber, 2007). For the OD field, the 
problem was initially defined as an inability to obtain a “reasonable 
profit,” which, in its turn, was proxied through a number of patients 
(Arno et al., 1995). But does this definition still hold? The more recent 
publications in economic, adaptation, dimension seem to focus on the 
analysis of the pricing strategies and that “rare diseases are the industry 
sector still generating two-digit growth numbers” (Bruyaka et al., 2013, 
p.55). 
Indeed, our review shows a discrepancy in the understanding of 
goals across the micro, meso, and macro levels: Regulations at the 
macro level intend to create conditions of economic sustainability; 
however, in practice, it is not what motivates companies to enter the 
OD development space (Bruyaka et al., 2013), and sometimes leads to 
unethical behaviors, which we call the “dark side” of the OD regula-
tions. Liu et al., (2010) suggested that combining government in-
centives for drug development, access to treatment, public awareness 
and registry, and price and purchase mechanisms could foster OD de-
velopment. Pharmaceutical companies, small and medium enterprises, 
and governmental and non-governmental organizations could all be 
engaged in these efforts. Role of patients and caretakers in knowledge 
accumulation, technology advancement, decision making and fund 
raising are two of the trends (T6 and 7) that change the landscape of the 
rare disease field and reinforce proactive, non-economic motivations 
for businesses (Rare 2030). Stephan et al., (2015) emphasize the im-
portance of simultaneous and complementary public and private in-
itiatives, suggesting that governmental engagement does not “crowd 
out” private pro-social initiatives such as social entrepreneurship. 
At the micro level, individual actors in society – e.g. patients, fa-
milies, and startups – are merely “small invisible hands” (Rip and 
Groen, 2001). However, the arrangements created across them can help 
understand the dynamics of society. As the co-evolution across society 
and technology (Rip and Kemp, 1998) causes a visible shift along the 
dimensions of goal attainment dimension toward including a broader 
range of powerful actors who want to and are ready to be involved, and 
latency dimension through upstream knowledge creation and adapta-
tion in the form of collective funding schemes. This shift along multiple 
dimensions of the social system will lead to adaptation of goals and 
strategic orientations of the field. 
Wicked problems, by their nature, “have no definitive formulation, but 
every formulation of a wicked problem corresponds to the formulation of a 
solution” (Buchanan, 1992, p.16). This means, that every solution is sub- 
optimal and not sufficient to solve the problem, but only to improve the 
situation. Thus, we argue that a regular cycle of revisiting the for-
mulation of the problem, actors, and goals is needed to make im-
provements on the aspects not taken into account at the previous re-
view round, make the system more complex and integrated and to fulfill 
the necessary set of functions – something that moves the entity toward 
its final state (Van de Ven and Poole, 1995). 
Dialog on prioritization of ODs 
Regulations of OD development at the macro level translate into 
practice through the approval procedures for the drugs that subse-
quently can or cannot enter the market. Our review has shown that the 
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traditional technical-economic logic of assessing new medication is not 
transparent and fails both, to provide a legitimate assessment process 
for ODs, and eliminate arguably unethical behaviors such as extra-
ordinary pricing, multiple indications, and stratification (Franken et al., 
2016). The discussion about the legitimacy of the procedures of drug 
approval is prominent in the reviewed literature. The consequences of 
OD pricing for access and equality are also highlighted by the stake-
holders in the field (T2, T5). 
Frameworks combining economic, ethical, innovation, product, and 
process stage aspects that aim to go beyond the pure effectiveness ar-
gument have been suggested (e.g. Wagner et al., 2016). Alternative 
assessment frameworks call for stimulating transparency, legitimacy, 
and openness in discussions about OD assessment procedures. This 
could lead to the elimination of the “dark side” of OD regulations, and 
to the collective sense of responsibility, where the innovator, as a 
member of a social group, “has to ask herself about the wider social and 
political significance of what she intends to accomplish” (Grinbaum and 
Groves, 2013, p.133). This can be achieved by means of an open, 
transparent, and fair public dialog about health priorities (Ehni, 2014;  
Reinecke and Ansari, 2016; Tierney et al., 2013). 
This dialog should take into account that the current public dis-
course adopts the “zero-sum game” framing and suggests that every 
dollar assigned to rare disease patients’ health care is a dollar the 
“general population has not received” (Dragojlovic et al., 2015). Multiple 
publications conducting pharmaco-economic analysis suggest, how-
ever, that ODs are not necessary presenting an immediate threat to the 
public budgets (Divino et al., 2016; Maresova et al., 2016;  
Schlander et al., 2015). The increased efforts for solidarity and equity 
on the global scale (T5) may help addressing this framing in order to 
give space to developments to combat rare diseases. The rare disease 
field is not the first to face such framing issue: Future research could 
possibly learn from other fields, such as the food versus fuel debate 
(Breukers et al., 2014; Buyx and Tait, 2011; Thompson, 2012). 
Novel technologies and business models for ODs 
The emergence of alternative drug development pathways and 
technologies is another important source of pattern renewal in the OD 
field. Technological developments drive faster drug research and in-
novation and make novel business models feasible. Alternative devel-
opment pathways may include drug discovery, rediscovery, and re-
direction and identifying potential new uses for compounds that have 
undergone significant R&D by the industry. Novel technological ad-
vancements, such as the promise of genomics, are noted and discussed 
in the literature. Rare2030 names trends that are going to change the 
field, among them, the increasing role of digital health (T8), large data 
sets (T9), use of AI (T10), advanced technologies and therapeutics 
(T11), and finally genome sequencing (T12). Embracing the possibi-
lities of Big data, internet of things and artificial intelligence may lead 
to Healthcare 4.0, named so paralleled to the Industry 4.0 (Islam et al., 
2020; Marinakis et al., 2017; Tortorella et al., 2020). 
However, advancement the technology greatly depends on the in-
volvement of researchers, clinical and patient groups, and private and 
regulatory actors in providing the data, as well as guidance and fi-
nancing for the biorepositories and drug commercialization 
(Feldman and Graddy-Reed, 2014; Ferlini et al., 2013; Godman et al., 
2015; So et al., 2013). Numerous efforts by the public and private sector 
initiatives are targeting creation of such programs and platforms at 
national, European or even Global level (Godman et al., 2015;  
Rubinstein and Groft, 2010; Vittozzi et al., 2013). Future research 
should identify how multi-stakeholder collaborations in creating sys-
tematic, usable and accessible registries should be governed and fi-
nanced to make the technological advancements possible. 
Sandler et al., (2002) argue that the coordination of transnational 
public goods should come from a multilateral organization acting on a 
consensual basis, such as public–private partnerships that tie together 
diverse players to develop, fund, and provide new drugs and treat-
ments. Recently, a new type of multilateral organization has been 
suggested: A mega fund. Fernandez et al., (2012) argued that increasing 
the scale of investment by pooling a big amount of development in-
itiatives in a single mega fund could address the problem of an over-
dependence on state financing. Initially proposed for cancer research, 
this financial entity amounting to between $5 billion and $15 billion, 
with the investors committing to make drugs for orphan diseases, could 
be sufficiently profitable by operating as a meso‑macro level platform 
to develop balanced drug portfolios (Maresova et al., 2016). Future 
research should identify, when and how OD can be a base for a prof-
itable yet responsible business model. 
Collaborative mechanisms across levels 
Discussion regarding regulations and their implementation that fo-
cused on their diversity across countries makes up by far the largest 
group of contributions in the review. At the macro level, evaluation and 
approval procedures across countries create conflicts that can prevent 
greater harmonization. Yet, each country faces its own set of challenges 
(Malets and Quack, 2013). While regulatory agencies are doing great 
work in aligning their processes and decision making criteria, chal-
lenges persist (Alqahtani et al., 2015). 
At the meso level, we see that the multidisciplinary dialog in the 
area of drug discovery and innovation is driving the pattern renewal. At 
present, there are more than 7000 rare diseases and a vast geographical 
dispersion of patients, clinicians, and researchers. It is, therefore, not 
surprising, that patient associations and foundations are being created 
to unite efforts around specific diseases and locations. National orga-
nizations in US and Canada (NORD and CORD, respectively), and 
ERORDIS in Europe mediate and guide these efforts on larger regional 
levels. However, technological developments also empower better and 
faster communication across borders and stakeholders. Integration, a 
common vocabulary, an ability to work across different dominant logics 
(Koelewijn et al., 2012; Lounsbury, 2007), and technological com-
plementarity are key to constructing usable and useful registries and 
biorepositories in order to make research in this area possible 
(Denis et al., 2010; Groft and Rubinstein, 2013). At the micro level, 
patients become more interested in complex solutions that would im-
prove the diagnosis process and are ready to be more involved in the 
process by actively participating in the drug innovation process 
(Huyard, 2009; Kesselheim et al., 2015; Wood et al., 2013). This is also 
supported by the trends observed by Rare2030 (T6, T7). Traditional 
role distribution may be questioned and redefined by informing the 
healthcare priorities. 
The previous discussion indicates the crucial role of collaborations 
that are multilateral and those that happen across levels, and how 
important it is to learn about the “how” and the “who” of multiple 
stakeholders constituting the ecosystem for OD development. It also 
highlighted the role of micro networks and the different types of sta-
keholders entering the scene in OD development. However, as few 
contributions focused on studying the mechanisms underlying and en-
abling this function in OD development, it is a current gap in the OD 
development literature which requires further investigation. With the 
complexities of the OD development and multi-stakeholder interactions 
at all times during the development process, this field offers significant 
opportunities for theory building that could be translated to other ad-
jacent fields and more management theory in general. 
Limitations and avenues for future research 
This paper is, of course, not without its limitations. First of all, in 
making this review we have solely focused on OD development. Despite 
the significant number of contributions and discussions, this search only 
considers the questions that were raised specifically in relation to OD 
development. This may, however, overlook the broader policy 
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measures and discussions in the rare disease field relevant for the dis-
cussion. Furthermore, while OD development is an important mission in 
addressing the societal challenge posed by rare diseases, it is not the 
only one. Proper and correct diagnosis of rare diseases is one of the 
major concerns for the patients. However, even accurately diagnosed, 
patients with rare conditions may be treated by physicians who have 
little evidence or guidance to help them. Furthermore, for some dis-
eases no disease-modifying therapies are known or are imaginable. 
Current treatment for these conditions still emphasizes treatment of 
symptoms and prevention of complications. While these include med-
ications, they could also include nutritional agents, surgical procedures, 
psychotherapy, physical and occupational therapy, complex medical 
devices (e.g., sophisticated communication devices), and less complex 
devices (e.g., braces). Future research could explore the mechanisms of 
adaptation, goal achievement, integration and latent pattern main-
tenance in the non-medicinal product and process areas. 
In making this review we have further relied on the traditional peer- 
reviewed publications, leaving a great number of reports that dis-
seminate recommendations provided by the leading national and pa-
tient-led organizations and target different areas of rare disease pre-
vention, diagnosis, management and treatment (development and 
delivery) out of the scope of this review. Future research may compare 
the insights gained from the traditional and upcoming (open source) 
and practitioner (gray literature) sources. 
Finally, this review has taken the knowledge about the development 
of ODs as “a stock”, highlighting the existing discussions, but not fol-
lowing the dynamics of these discussions over time or across borders. 
Future research could focus more on the dynamics of the field. For 
example, by investigating conditions, under which it became more in-
teresting and profitable for big pharma to enter the OD development, 
and what led to the so-called “dark side” of the OD regulations. As 
many contributions in this review have extensively compared the state 
of rare disease drug development, assessment and approval across 
various combinations of countries and continents, we have opted to not 
anchor our findings in any specific geographical location. However, as 
differences exist, the reader may want to assess the applicability of 
these identified general trends and research avenues for the local si-
tuation. 
The analysis of the contributions and the discussion above that 
highlight the research gaps along the goal attainment, adaptation, in-
tegration and latency dimensions allow us to identify some directions 
for future research.  
(1) What are the suitable multi-lateral multi-stakeholder governance 
models? Constructive dialog of multiple stakeholders with diverse 
goals and logics is needed to address any wicked problem. 
Stakeholders in the rare disease field extensively collaborate with 
actors from social sciences, health policy, regulatory science, 
eHealth, big data, -omics approaches, bioinformatics, nano-
technology, etc. (Groft and Rubinstein, 2013). This has resulted in 
significant advances of the field. What are the underlying govern-
ance mechanisms of these collaborations? How do the stakeholder 
engagement and management strategies reflect the unique chal-
lenges of the OD development process? Can these insights inspire 
solutions to other wicked problems?  
(2) Do deliberative stakeholder involvement strategies differ across fields? In 
multi-stakeholder networks, what is a good balance of diversity to 
ensure that integration, a common vocabulary, and technological 
complementarity are possible? How do they adjust to the new en-
trants and changing roles of the existing participants? A.o. Are there 
special strategies that patients need to keep in mind when engaging 
in conversation with science, business, and regulatory bodies? Can 
these insights inform other fields, such as user or open innovation 
(West and Bogers, 2014), where users change their roles, or In-
dustry 4.0 stream of work that welcomes novel and non-traditional 
players (Stelzer et al., 2015)? 
(3) What are the limits of patient involvement in OD deliberative democ-
racy? The shift at the micro level toward greater initiative and more 
entrepreneurship is very important and meaningful. At the same 
time, it raises the question of whether one can expect families and 
patients who are already suffering to assume more responsibility 
and take charge of new developments. Scherer and Palazzo (2011) 
have questioned the limits of downstreaming the responsibility 
(p. 919), but in the field of rare diseases, patients and caretakers 
have shown that they are ready and able to take on this responsi-
bility by shifting from the role of consumer to that of supplier 
(Oliveira et al., 2019; Oliveira et al., 2015; Wood et al., 2013). 
Under what conditions could this be a pathway forward? Further-
more, as patients and patient organizations more often than not 
focus on their own disease, to what extend can technological ad-
vances of Healthcare 4.0 (Islam et al., 2020; Tortorella et al., 2020) 
stimulate systematic creation of rare disease registries?  
(4) What are the novel business models? Existing business models rely 
heavily on the government incentives and possibilities of exploiting 
existing (matching) technological capabilities. Some studies report 
unethical business practices that allow niche-buster profits. Under 
what conditions can business models for ODs be sustainable? 
Portfolio business models and multilateral funding schemes seem to 
show promise here. What are the primary enablers and (ethical) 
consequences of these business models? Are there other novel 
business strategies that create both economic and social value?  
(5) Does “personalized” mean “prioritized”? The “4 P's” trend in 
Healthcare (predictive, preventive, personalized and participatory 
healthcare) is changing how we embrace healthcare and innovate 
pharmaceutical treatments (Denicolai and Previtali, 2020;  
Tierney et al., 2013). A potential research stream focusing on the 
healthcare trend of the 4P's, ODs and prioritization is an important 
element in such a discussion. 
(6) What is the price of knowledge? With the importance of harmoniza-
tion, collaboration, sharing and transparency in the OD develop-
ment field another question that comes to mind is the price of 
knowledge. The concept of an Abundant economy is relevant here. 
This concept suggests that sharing information does not diminish 
either the generator nor receiver value (Gary et al., 2020). Future 
research streams which investigate the changing nature of an I4.0 
information-based economy, cryptocurrencies (White et al., 2020) 
and the value of information sharing in the case of OD development 
in the light of the 4P's trend in healthcare would be exceptionally 
valuable research streams.  
(7) A final research avenue could explore the idea of the ownership in 
the OD space. With the importance of mutual efforts of various 
stakeholders in creating conditions that make OD development ef-
forts possible and sustainable, what is a “reasonable profit” 
(Denis et al., 2010), and who has the right for the extraordinary 
(blockbuster) profits from ODs (Godman et al., 2015)? Does the tax, 
reimbursement and compensation system reflect the shared risk 
philosophy behind the 4P healthcare system in terms of in-
appropriate innovations (Radaelli et al., 2017) and risks of trans-
ferring medical science to the market (Erzurumlu and 
Pachamanova, 2020)? 
CONCLUSION 
Our review shows that 35 years into creating a unique space for OD 
development, the academic debate is heavily dominated by the dis-
cussions on economic stimuli (market exclusivity), economic grounds 
(cost-effectiveness analysis), cost and expenditure, and the financial 
malpractices of corporations. In analyzing the issue, the dominance of 
economic reasoning suggests the problem lies with individual actors’ or 
companies’ inability to finance the gap created by a market failure. All 
of these discussions, despite residing in regulatory or strategic domain 
are fueled by the economics logic. As government is the main guarantor 
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of stability and a fair redistribution of public money, it is only natural to 
look to the government, and great progress has been done in the past 
years towards elimination of this societal challenge. However, new 
approaches to accumulate funds or to reduce the need for funding have 
been suggested as a result of the adaptation and development of the 
field, and could augment the current efforts and open new opportu-
nities. 
Furthermore, analyzing the system from the point of view of social 
interactions provides additional insight highlighting the importance 
and potential of involving patients and parents in knowledge accumu-
lation, technology advancement, decision making, and fundraising. 
However, research needs to advance to better support this develop-
ment: we still need a better understanding of the mechanisms behind 
the multi-actor initiatives in the OD field, and how the recent trends in 
patient and patient advocacy empowerment will influence the gov-
ernance of the multi-stakeholder collaborations. 
Last, as we perform our socio-systemic analysis and reconstruct the 
field of OD development along the AGIL dimensions, we are able to see 
the conflict of logics applied with the problems at hand. We are also 
able to link together solutions coming from different research streams 
and disciplines that address the similar dimension of the social system 
through a different disciplinary lens. This provides a balanced tool for 
analysis of complex developments, such as management of a solution to 
a global challenge, and a useful lens to identify future avenues for re-
search. 
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